12 March 2002
Eradication of Helicobacter pylori in duodenal ulcer disease tetracycline & furazolidone vs. metronidazole & amoxicillin in omeprazole based triple therapy.
Mohammad S Fallah, Fariborz Mansour-Ghanaei, Afshin ShafaghiMed Sci Monit 2002; 8(3): PI27-30 :: ID: 420887
Abstract
BACKGROUND: The object of the study was to study the efficacy and safetyof furazolidone and tetracycline compared to metronidazole and amoxicillin in an omeprazole based tripletherapy in a prospective randomized-blind-clinical trial. MATERIAL/METHODS: Patients with endoscopicallyverified active duodenal ulcer disease in the presence of Helicobacter pylori infection were eligibleto enter the study. Endoscopy was performed a day before and 6-8 weeks after the cessation of treatment.H. pylori status was assessed by histologic examination (Giemsa stain) of biopsy specimens were takenfrom the antrum and corpus. H. pylori eradication was defined as absence in histology of the biopsy specimensat the second endoscopy. Ulcer healing was considered as decrease in ulcer size to less than 20% of itsprimary size. Patients were randomly assigned to receive omeprazole 20 mg, amoxicillin 1000 mg and metronidazole500 mg (OAM group) or omeprazole 20 mg, tetracycline 500 mg and furazolidone 200 mg (OTF group). Allmedications were taken twice daily, for 2 weeks. RESULTS: Out of 111 patients enrolled in the study,108 completed a course of treatment and underwent a follow-up endoscopy, with 54 patients in each group.H. pylori eradication was achieved in 52 patients (96.3% - 95% CI: 91.27-100) in OTF group and 45 patients(83.3% - 95% CI: 73.35-93.25) in OAM group (P=0.015). Our study showed the superiority of OTF vs. OAMregimen with a 13% increment in eradication rate, with only occasional severe side effect. CONCLUSIONS:In conclusion OTF regimen is a safe, cheaper and effective alternative for OTF regimen and we recommendit to be used especially in developing countries.
Keywords: Amoxicillin, Anti-Bacterial Agents, Anti-Infective Agents, Local, Antibiotics, Combined, Duodenal Ulcer, furazolidone, Helicobacter pylori, metronidazole, Tetracycline
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
11 Mar 2024 : Clinical Research
Enhancement of Frozen-Thawed Human Sperm Quality with Zinc as a Cryoprotective AdditiveMed Sci Monit In Press; DOI: 10.12659/MSM.942946
12 Mar 2024 : Database Analysis
Risk Factors of Age-Related Macular Degeneration in a Population-Based Study: Results from SHIP-TREND-1 (St...Med Sci Monit In Press; DOI: 10.12659/MSM.943140
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952